Related Experiment Video

Updated: Feb 1, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.0K

Necitumumab for the treatment of advanced non-small-cell lung cancer

Asunción Díaz-Serrano1,2, Ana Sánchez-Torre1, Luis Paz-Ares1,2,3,4

  • 1Medical Oncology Department, Hospital Universitario 12 de Octubre. Madrid, Spain.

Future Oncology (London, England)
|December 4, 2018
PubMed

Insights

Necitumumab, an anti-EGFR antibody, is a new first-line option for advanced squamous non-small-cell lung cancer (NSCLC). Combined with chemotherapy, it improves survival and disease control, but biomarker research is ongoing.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunotherapy

Background:

  • Personalized medicine is advancing non-small-cell lung cancer (NSCLC) treatment.
  • The epidermal growth factor receptor (EGFR) pathway is a validated target in NSCLC.
  • Monoclonal antibodies targeting EGFR, like necitumumab, are being investigated.

Purpose of the Study:

  • To evaluate necitumumab as a first-line treatment for advanced squamous NSCLC.
  • To assess the efficacy of necitumumab in combination with chemotherapy.
  • To identify areas for future research in EGFR-targeted therapy for NSCLC.

Main Methods:

  • Phase III SQUIRE trial.
  • Necitumumab (humanized IgG1 anti-EGFR) administered with cisplatin and gemcitabine.
  • Evaluation of risk-of-death and disease control rate.

Main Results:

  • Necitumumab plus chemotherapy demonstrated a reduced risk-of-death in advanced squamous NSCLC.
  • Improved disease control rates were observed with the combination therapy.
  • Necitumumab is established as a new first-line treatment option.

Conclusions:

  • Necitumumab offers a new first-line treatment strategy for advanced squamous NSCLC.
  • Further biomarker research is crucial for optimizing patient selection.
  • Combination of necitumumab with immunotherapy and targeted agents is a promising research direction.
Keywords:
EGFREGFR inhibitorIMC-11F8INSPIRE trialNSCLCSQUIRE trialepidermal growth factor receptormonoclonal antibodynecitumumabnon-small-cell lung cancersquamous cell carcinomatargeted therapy

More Related Videos

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

415

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups


Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.9K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.2K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K